Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split

June 26, 2026
By Ethan Parker

Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split

Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib; Company reaffirms guidance for dosing of initial five patients by end of July 2026 with data expected December 2026; Stockholders approve reverse stock split LEXINGTON,…

Read the full release →

News provided by PR Newswire.

Must read

All Posts
Art Community
Art Exhibitions and Features
Art Exhibitions Features
Art History
Art Work
Artistic Journeys
Artwork
Community Well-Being
Design Inspiration
Press Releases
Uncategory

Think Outside the Cup for 7-Eleven, Inc.'s Bring Your Own Cup Day

Think Outside the Cup for 7-Eleven,…

September 10, 2026

The Salvation Army Marks 25 Years Since 9/11 With Stories of Service and a Call to 'Be That Something'

The Salvation Army Marks 25 Years…

September 8, 2026

Lemonade CFO to Participate in Upcoming…

September 8, 2026

Genesis wins AFR Sustainability Leaders 2026…

September 8, 2026

China Merchants Bank Wins CNCF End…

September 8, 2026

Cell Stem Cell: tBE-mediated Base Editing…

September 8, 2026